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To the Editor: 
 
CD19-directed CAR T cell therapy (CD19-CAR-TCT) has been successful as a novel modality in treating 
recurrent or refractory B-lineage acute lymphoblastic leukemia (B-ALL) (1-2). Despite absence of 
circulating B lymphocytes, severe pan-hypogammagobulinemia, decreased plasma cell (PC) content 
and B cell aplasia in tissues, persistence of some humoral immune response mediated by remaining 
CD19-negative PC was shown following CD19-CAR-TCT (3). The authors further emphasized the need 
for investigating mucosal antibodies in these patients. Our case constitutes an example of potential 
CD19-CAR-TCT complication due to impaired secretory immune response. 
A, currently, 10-year-old female with standard-risk B-ALL started treatment before relocating to 
the United States in 2011. She also has history of vitamin B12 deficiency from infancy, which later 
was discovered to be due to hereditary intrinsic factor deficiency (4-5). She continued treatment, but 
experienced systemic relapse 22 months from diagnosis while receiving maintenance chemotherapy. 
She was then treated per the UK ALL-R3 regimen, but did not achieve complete remission. She 
underwent matched sibling bone marrow transplantation (BMT) relapsing in the bone marrow 5 
months after BMT. Following clofarabine and cytarabine chemotherapy, she developed secondary 
hemophagocytic lymphohistiocytosis with multi-organ failure. However, she achieved and had 
remained in complete remission for 10 months. Due to systemic relapse, she underwent CD19-CAR-
TCT at another institution 28 months ago. She has been supplemented with intravenous 
immunoglobulin regularly and continues to be in remission with undetectable peripheral blood B 
lymphocytes and serum IgA and IgM levels. 
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 Prior to CD19-CAR-TCT, the patient had 3 separate urinary tract infections (UTI) secondary to E. coli 
during 40 months of follow up, which clustered in less than a 3-month period and corresponded to 
the time of BMT when she was on graft-versus-host disease prophylaxis. Both immune suppression 
and possible incomplete eradication supported by the observation of short intervals between UTI 
episodes might have contributed to recurrence. She had 3 UTI episodes 14, 18 and 23 months 
after CD19-CAR-TCT due to E. coli and P. mirabilis with negative renal/bladder ultrasound and 
voiding cystourethrography studies. Salivary secretory IgA (sIgA) levels were very low on two 
measurements at 0.31 and 0.35, respectively (normal: 5-28). 
Secretory IgA predominates the immunoglobulin content in secretions and is produced by local 
stromal or nodal tissue PC along with joining (J) chain, which binds two or more IgA monomers that 
associates with an epithelial glycoprotein called ‘secretory component’ facilitating secretion to 
mucosal surfaces. Monomeric IgA can be also found in mucosal secretions, making 13-17% of the 
salivary IgA and 77% of the salivary monomeric IgA that is estimated to be serum-derived (6). 
Secretory IgA is critical in mucosal pathogenic microorganism colonization by preventing bacterial 
adherence, agglutinating microorganisms, interfering with bacterial motility and neutralizing 
bacterial enzymes and toxins (7). Furthermore, binding of sIgA by E. coli protein was shown to inhibit 
neutrophil activation (8).  
Low urinary tract sIgA has been linked to recurrent symptomatic bacteriuria in females with normal 
urinary tracts (9). While salivary sIgA does not directly reflect urine sIgA status, it may suggest 
possible low sIgA level in the urine. Thus, low salivary sIgA should warrant testing sIgA levels in the 
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